STEMTECH CORPORATION INVITED TO PRESENT AT ROTH CAPITAL HEALTHCARE OPPORTUNITIES CONFERENCE IN NEW YORK CITY
Stemtech Corporation (OTCQB: STEK), a leader in stem cell nutrition, announced its invitation to present at the Roth Capital Healthcare Opportunities Conference in New York City on October 6. CEO Charles S. Arnold expressed pride in being part of this prestigious event, highlighting the company's focus on stemceuticals that enhance immune function and promote health and wellness.
Founded in 2005, Stemtech specializes in innovative nutraceutical products, which are plant-based and manufactured under stringent quality standards. The company aims to boost the body's adult stem cells for improved quality of life.
- None.
- None.
MIRAMAR, FL, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today that it was invited to present at the Roth Capital Healthcare Opportunities Conference in New York City on October 6.
Stemtech Corporation CEO Charles S. Arnold says that “it is an honor for Stemtech to be invited to present at such a prestigious forum as the Roth Capital Partners event. The conference is focused on healthcare companies in Biotechnology and Pharmaceuticals. Stemtech Corporation is the pioneer in stem cell nutrition, with focus on immune system boosting stemceuticals™ addressing anti-aging, longevity and improving quality of life products, health and wellness since its founding in 2005.”
Mr. Arnold continues to say that “Stemtech’s belief in highly efficacious and quality products expands into a very important area of strategic focus on healthcare through stem cell nutrition.”
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem, OraStem® (Oral Health Care), and D-Fuze™ (EMF blocker). Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on August 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
Investor Relations:
Investor Relations: 954-715-6000 ext 1040
invrel@stemtech.com
FAQ
What did Stemtech announce on October 4, 2022?
Who is the CEO of Stemtech Corporation?
What is the focus of Stemtech's products?
When was Stemtech Corporation founded?
What type of products does Stemtech offer?
